8,830 results on '"Krag A"'
Search Results
102. OS-059 Unveiling Socioeconomic Disparities on Liver Disease: A Comparative Study of ALD, MASLD, and MetALD Patients
103. TOP-241-YI Longitudinal changes in liver stiffness measurements in a population-based screening cohort of 5, 517 participants
104. SAT-250 Substituting FIB-4 with LiverPRO as an initial test for detecting advanced fibrosis leads to a 6-fold reduction in false positive results
105. SAT-266 Fibrosis stage progression in alcohol-related liver disease evaluated by repeated biopsies
106. OS-126 Steatotic liver disease classification is highly dynamic impacting eligibility for clinical trials and subclass-specific interventions
107. WED-199 Optimizing MASLD trial recruitment: LiverPRO vs. FIB-4 in reducing false positives and unnecessary biopsies
108. TOP-012 Validation of transient elastography and the enhanced liver fibrosis test as prognostic biomarkers across the spectrum of steatotic liver disease
109. SAT-255 Assessing LSM thresholds to identify clinically relevant SLD in individuals with excessive alcohol intake and absence of steatosis
110. OS-072-YI Identifying patterns of steatotic liver disease severity: a multiomic analysis of 834 distinct omics features from healthy to end-stage liver disease in 854 individuals
111. WED-135-YI Impact of metabolic alterations on liver phenotype of patients with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ)
112. FRI-045 Superior prognostic accuracy of the LiverPRO score versus FIB-4 in predicting liver-related events in a cohort of 457, 152 individuals
113. OS-038-YI Real-world practice patterns on the use of terlipressin in patients with cirrhosis and acute kidney injury-results from the ICA-GLOBAL AKI study
114. THU-055 Differential impact of proton pump inhibitors, statins, and nonselective beta-blockers on survival in different stages of chronic liver disease
115. TOP-141 Longitudinal assessment of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype) provides evidence for clinical patient management
116. FRI-017 Fibrosis activity versus disease stage: systemic markers of fibrosis activity have better prognostic performance than the liver biopsy in patients with alcohol-related liver disease
117. FRI-041 Evaluating the influence of human albumin infusions on the MELD and MELD-Na scores in patients hospitalized with an acute decompensation of cirrhosis: an ATTIRE trial analysis
118. OS-041-YI A spatiotemporal map of the hepatocyte proteome in alpha-1 antitrypsin deficiency by single-cell and visual proteomics
119. Long-term effects of restriction of intravenous fluid in adult ICU patients with septic shock
120. Why diversity among participants in clinical studies is not always preferable: the case for small, exploratory studies
121. A Serological Biomarker of Laminin Gamma 1 Chain Degradation Reflects Altered Basement Membrane Remodeling in Crohn’s Disease and DSS Colitis
122. Noninvasive proteomic biomarkers for alcohol-related liver disease
123. Novel Homozygous Truncating Variant Widens the Spectrum of Early-Onset Multisystemic SYNE1 Ataxia
124. Quantification of catch composition in fisheries: A methodology and its application to compare biodegradable and nylon gillnets
125. Low aerobic capacity in McArdle disease: A role for mitochondrial network impairment?
126. Functional brain connectivity in electrical status epilepticus in sleep
127. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
128. Short‐term temporal variation of coastal marine eDNA
129. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
130. The positive prediction of single photon emission computed tomography/ computed tomography (SPECT/CT) in the outcome of intervention for cervical facet pain
131. The effects of pantoprazole vs. placebo on 1-year outcomes, resource use and employment status in ICU patients at risk for gastrointestinal bleeding: a secondary analysis of the SUP-ICU trial
132. Impact of artificial waterholes on temporal partitioning in a carnivore guild: a comparison of activity patterns at artificial waterholes to roads and trails
133. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
134. Are Nonalcoholic Fatty Liver Disease and Bone Mineral Density Associated? — A Cross‐Sectional Study Using Liver Biopsy and Dual‐Energy X‐Ray Absorptiometry
135. Impact of Non-etiological Novel Therapies in the Course of Cirrhosis: Consensus Statements of Panel 4
136. Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis
137. Increased activity of the metalloproteinase PAPP-A promotes diabetes-induced glomerular hypertrophy
138. Serologically assessed heat shock protein 47 is related to fibrosis stage in early compensated alcohol-related liver disease
139. Artificial intelligence outperforms standard blood-based scores in identifying liver fibrosis patients in primary care
140. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
141. Electrocardiographic characteristics of trained and untrained standardbred racehorses
142. Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project
143. Development and external validation of a model to predict multidrug‐resistant bacterial infections in patients with cirrhosis.
144. Prokinetic agents in adult intensive care unit patients (PATIENCE)—An international inception cohort study protocol.
145. Selective decontamination of the digestive tract in burn patients: Protocol for a systematic review.
146. Hemostatic Effects of Exercise-related Hypoglycemia in Male Persons With Type 1 Diabetes.
147. NEGLECTED RICHES: EXPOSING CHINA'S SELECTIVE DEFAULT ON THE HUKUANG RAILWAY BONDS AND THE AVENUE FOR FINANCIAL ACCOUNTABILITY UNDER THE SUCCESSOR GOVERNMENT DOCTRINE.
148. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.
149. Alcohol consumption and liver phenotype of individuals with alpha‐1 antitrypsin deficiency.
150. Clinical effects of SGLT2 inhibitors in seven persons with HNF1A‐MODY (MODY3).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.